Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Recruiting 2Active not recruiting 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Carcinoma, Renal Cell 37Parkinson Disease 4, Autosomal Dominant Lewy Body 7Neoplasm Metastasis 4Kidney Neoplasms 4Carcinoma, Transitional Cell 4Squamous Cell Carcinoma of Head and Neck 3Endometrial Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2Ovarian Neoplasms 2Melanoma 2Clear-cell metastatic renal cell carcinoma 2Brain Neoplasms 2von Hippel-Lindau Disease 1Urologic Neoplasms 1Urinary Bladder Neoplasms 1Thrombocytosis 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Penile Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Myeloproliferative Disorders 1

Interventions

aldesleukin 43Sunitinib 42Cyclophosphamide 30Nivolumab 29pembrolizumab 27Everolimus 27Interferon-alpha 25Bevacizumab 23Sorafenib 22Interleukin-2 20fludarabine phosphate 19Radiotherapy 18Ipilimumab 18Filgrastim 18Axitinib 18Gene Expression Profiling 16Peripheral Blood Stem Cell Transplantation 15Gemcitabine 15cabozantinib 14Radiosurgery 13fludarabine 11Doxorubicin 11Carboplatin 11Blood Specimen Collection 11temsirolimus 10atezolizumab 9Immunohistochemistry 9Etoposide 9Chemotherapy, Adjuvant 9sargramostim 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Kidney Neoplasms × lenvatinib × Genitourinary × Clear all
NCT04393350 2026-04-20

Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma

Emory University

Phase 2 Active not recruiting
18 enrolled 12 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT05030506 2025-12-18

MK-6482-010

Merck Sharp & Dohme LLC

Phase 1 Active not recruiting
45 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT06962787 2025-11-17

A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 2 Recruiting
260 enrolled
Genitourinary

Kidney Neoplasms

NCT06364631 2025-01-16

CARE1

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3 Recruiting
1,250 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔